The cardioprotective properties of extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) are currently being investigated in preclinical studies. Although microRNAs (miRNAs) encapsulated in EVs have been identified as one component responsible for the cardioprotective effect of MSCs, their potential off-target effects have not been sufficiently characterized. In the present study, we aimed to investigate the miRNA profile of EVs isolated from MSCs that were derived from cord blood (CB) and adipose tissue (AT). The identified miRNAs were then compared to known targets from the literature to discover possible adverse effects prior to clinical use. Our data show that while many cardioprotective miRNAs such as miR-22-3p, miR-26a-5p, miR-29c-3p, and miR-125b-5p were present in CB-and AT-MSC-derived EVs, a large number of known oncogenic and tumor suppressor miRNAs such as miR-16-5p, miR-23a-3p, and miR-191-5p were also detected. These findings highlight the importance of quality assessment for therapeutically applied EV preparations.
CITATION STYLE
Nazari-Shafti, T. Z., Neuber, S., Duran, A. G., Exarchos, V., Beez, C. M., Meyborg, H., … Emmert, M. Y. (2020). Mirna profiles of extracellular vesicles secreted by mesenchymal stromal cells—can they predict potential off-target effects? Biomolecules, 10(9), 1–50. https://doi.org/10.3390/biom10091353
Mendeley helps you to discover research relevant for your work.